Lumida
/FENC
⌘K
Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc

FENC
$10.50USD↑+0.57%+0.06 today

MARKET CAP

364.7M

P/E (TTM)

—

FWD P/E

20.1x

DAY RANGE

$10 – $11

52W RANGE

$6
$11

AI Summary

Stalk
StalkMedium

FENC remains in a high-confidence Stage 2 advancing uptrend with an active momentum breakout confirming medium-term bullish structure, but price is currently extended above rising EMAs with overbought RSI and options score, making short-term execution unfavorable; deferred entries on a healthy pullback into support are advised.

  • ↑Q1 2026 net product sales rose 73% YoY to $15.1M
  • ↑Generated positive cash flow in Q1; holds $40.1M in cash
  • ↓Profitability remains weak; Q1 operating expenses hit ~$14M
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) is a biotechnology company focused on developing and commercializing therapies to prevent cisplatin-induced ototoxicity, particularly among pediatric and adolescent populations. As the innovator of PEDMARC, the first FDA-approved therapy for this condition, Fennec is well-positioned within the oncology treatment value chain, addressing a significant unmet need in cancer care that aligns with broader themes of advancing supportive care within oncology.

Bull says

  • ↑Q1 2026 net product sales rose 73% YoY to $15.1M
  • ↑Generated positive cash flow in Q1; holds $40.1M in cash
  • ↑Analysts lifted targets from $13 to $16 on PEDMARC uptake
  • ↑Project Ignite and HEARS programs expand prescriber reach
  • ↑AYA market of ~20,000 cisplatin patients underpins growth
  • ↑Strong growth and momentum factors suggest upside potential

Bear says

  • ↓Profitability remains weak; Q1 operating expenses hit ~$14M
  • ↓Guided ~$50M total Opex in 2026 amid $4M Q1 cash burn
  • ↓Established oncology drugs and scale disadvantage may hinder adoption
  • ↓International rollout may face regulatory delays and market hurdles
  • ↓Weak profitability and size factors plus high volatility risk
  • ↓Competition from big oncology players could slow market share

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-20-2026bullish

Transcript signals

Bull points

  • For the first quarter of 2026, the company recorded net product sales of 15.1 million, compared to 8.8 million in the first quarter of 2025, representing an increase of approximately 73% year-over-year compared with the first quarter of 2025.
  • The first quarter demonstrated continued momentum in delivering Pedmark to patients with net product sales up for the sixth consecutive quarter since new commercial leadership took over.
  • We saw record new patient enrollments in the March quarter, and April was our highest demand month ever.

Bear points

  • With regard to anticipated milestone payments from our partner, Norgene, we do not anticipate receiving the German milestone payment.
  • which we define as R&D and SG&A excluding stock-based compensation, it was approximately $14 million for the quarter, with a year-over-year increase of approximately $6 million.
Read full transcript analysis ›